Law
Offices of Howard G. Smith announces that it is investigating
potential claims on behalf of investors of Northwest Biotherapeutics,
Inc. (“Northwest Biotherapeutics” or the “Company”) (NASDAQ:NWBO). The
investigation concerns possible violations of federal securities laws
and focuses on certain statements issued by Northwest Biotherapeutics
concerning the Company’s operations and prospects.
Northwest Biotherapeutics is a biotechnology company engaged in the
discovery and development of immunotherapy products to treat cancers in
the United States and internationally. The Company is involved in the
development of DCVax, a platform technology that uses activated
dendritic cells to mobilize a patient’s own immune system to attack
cancer. The investigation is related to an article published June 19,
2014, by TheStreet.com, alleging that the MD Anderson Cancer
Center “issued a stern rebuke to Northwest Biotherapeutics for making
promotional, unjustified claims about results from an ongoing clinical
trial of an experimental cancer vaccine known as DCVax-Direct.” The
article further alleges that the vice president of clinical research at
the MD Anderson Cancer Center stated that claims in certain of the
Company’s press releases concerning the DCVax-Direct clinical trials are
preliminary and unconfirmed. Following this news, the price of Northwest
Biotherapeutics shares dropped nearly 20 percent in intraday trading on
June 19, 2014.
If you purchased Northwest Biotherapeutics securities, if you have
information or would like to learn more about these claims, or if you
have any questions concerning this announcement or your rights or
interests with respect to these matters, please contact Howard G. Smith,
Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite
112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll
Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at www.howardsmithlaw.com.
Copyright Business Wire 2014